Radioimmunotherapy for non-Hodgkin's lymphoma (Q35206373)

7 August 2017

1 reference

title

Radioimmunotherapy for non-Hodgkin's lymphoma. (English)

1 reference

7 August 2017

author name string

Christos Emmanouilides

series ordinal

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

page(s)

531-544

1 reference

Radioimmunotherapy: recent results and future directions

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Milestones in the development of Lym-1 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Rationales, evidence, and design considerations for fractionated radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Radioimmunotherapy in the π-BCL1 B cell Lymphoma Model: Efficacy Depends on More Than Targeted Irradiation Alone

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Radionuclide-antibody conjugates for single-cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Choosing an optimal radioimmunotherapy dose for clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900237-9

7 January 2021

10.1016/S0093-7754(03)00237-9

Identifiers

DOI

1 reference

7 August 2017

1 reference